← Eichor
Condition: Stem Cell Donors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Stem Cell Donors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Re
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07225985Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
Phase 4 · 1 location(s) · Suping ZHANG · NCT06339775Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Tran
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05443425Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06839456Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa
Phase 1 · 3 location(s) · City of Hope Medical Center · NCT07020533Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT06326008Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploid
Phase 2 · 5 location(s) · Rongrong Liu · NCT06657391Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
Phase 1/Phase 2 · 1 location(s) · Jeffrey Veale, MD · NCT03707262CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3 · 1 location(s) · Peking University People's Hospital · NCT07441291Individualized Application of Anti-Thymocyte Globulin(ATG)in Unrelated Donor Hematopoietic Stem Cell Transplantation
Phase 4 · 1 location(s) · Daihong Liu · NCT07648992211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymph
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03128034Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan
Phase 1/Phase 2 · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT05463133Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Phase 1/Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT07599176CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation
Phase 2 · 1 location(s) · Hong Kong Children's Hospital · NCT06034535Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Yo
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT06756152HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell De
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT07052370Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase 2 · 3 location(s) · Sawa Ito, MD · NCT06529731A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditionin
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06564493T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Phase 1/Phase 2 · 1 location(s) · Paul Szabolcs · NCT03653338A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transpl
Phase 3 · 26 location(s) · TScan Therapeutics, Inc. · NCT07702578A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Ce
Phase 1 · 21 location(s) · TScan Therapeutics, Inc. · NCT05473910RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease
Phase 3 · 1 location(s) · King's College Hospital NHS Trust · NCT05392894Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210Immune Reconstitution in Stem Cell Transplant Recipients
Phase N/A · 1 location(s) · University of Miami · NCT02129543Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment
Phase 3 · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06705062Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors
Phase 2 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT07570745REVEAL Biomarkers of Engraftment After Alternative Donor HSCT
Phase 1 · 4 location(s) · University of Oklahoma · NCT03541889MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.